PureTech’s deupirfenidone slows lung function decline in IPF
UK-based PureTech Health (LSE: PRTC) has announced positive results from ELEVATE IPF, a Phase IIb trial of deupirfenidone (LYT-100) at two dose levels, three times a day (TID) over 26 weeks in patients with idiopathic pulmonary fibrosis (IPF).
Shares in the London firm were 6% higher by lunchtime on Monday, when the trial results were announced. The company described the data as remarkable, particularly for a monotherapy, and – if supported by a Phase III trial – claim that it would represent a step change in the treatment of IPF.
Our goal in developing deupirfenidone is to offer better outcomes to people living with IPF
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze